The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Dupilumab use in asthma is linked to higher lymphoma risk, especially T and NK cell types, but also shows reduced all-cause ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis ...

More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...